Background: There is no effective treatment for idiopathic tinnitus. Both acoustic therapy and acupuncture have been used in the treatment of idiopathic tinnitus, but the clinical efficacy is quite different. For there is no clinical study combining the 2, the purpose of this randomized controlled trial is to evaluate the effectiveness and safety of acoustic therapy combined with acupuncture in the treatment of idiopathic tinnitus. Methods: This is a prospective randomized controlled trial to study the effectiveness and safety of acoustic therapy combined with acupuncture in the treatment of idiopathic tinnitus, and is approved by the clinical research ethics committee of our hospital. The patients are randomly divided into one of 2 treatment options: (A) acoustic therapy combined with acupuncture group and (B) simple acupuncture group. Patients, doctors, nurses, and data collection assistants are blinded to group allocation. Observation indicators include: Data is analyzed using the statistical software package SPSS version 25.0 (Chicago, IL). Discussion: This protocol will evaluate the efficacy and safety of acoustic therapy combined with acupuncture in the treatment of idiopathic tinnitus. The results of this experiment will provide clinical evidence for the use of acoustic therapy combined with acupuncture in the treatment of idiopathic tinnitus. Trial registration: This study protocol is registered in Ethics and dissemination: Private information from individuals will not be published. This systematic review also does not involve endangering participant rights. Ethical approval was not required. OSF Registration number: DOI 10.17605/OSF.IO/87VFB.
Background Hearing loss is a common disease globally, and more than 50% of the cases are genetic. Autosomal recessive nonsyndromic hearing loss (ARNSHL) is one of the most common types of hereditary hearing loss. Here, a novel MYO15A missense mutation was identified in a Chinese family with ARNSHL, using targeted genetic sequencing and Sanger sequencing. Case presentation: A 6-year-old girl with congenital nonsyndromic sensorineural deafness was presented from the First Affiliated hospital of Chongqing Medical University, China. We used targeted region sequencing, Sanger sequencing, functional prediction, and three-dimensional protein structure modeling to identify and verify the genes responsible for deafness in the family. Conclusions We found pathogenic compound heterozygous mutations in MYO15A, including a novel missense mutation, c.6353T > C (p.Leu2118Pro). It could provide help not only for genetic counseling but also for further understanding of the functional role of MYO15A mutations.
Objectives: Sudden sensorineural hearing loss (SSNHL) is an emergency disease with undefined pathogenesis in the otolaryngology department. In our previous study, we found patients with SSNHL had lower serum concentration of Matrix metalloprotease 9 (MMP-9) than healthy controls, and the result was accordant with auto-immune diseases. This study aimed to reveal the correlation between changes in serum MMP-9 concentration following treatment with the outcomes of patients and to provide further evidence that immune disorder was the main pathogenesis of SSNHL. Design, setting, and participants: Fifty-two patients with SSNHL, hospitalized in The First Affiliated Hospital of Chongqing Medical University from March 2019 to August 2019, were enrolled. The serum concentration of MMP-9 was detected by enzyme-linked immunosorbent assay (ELISA). Main outcome measure: The mean concentration of MMP-9 before treatment was compared with the post-treatment concentration by the Mann-Whitney U test. The correlations between favorable outcomes of patients and clinical characteristics were measured with the Chi-squared test and binary multiple logistic regression analysis. Results: In treatment responders, mean serum concentration was elevated from 106.85±41.40ng/ml to 144.03±37.65 ng/ml following treatment (P¡0.001), while in non-responders it decreased from 132.09+-59.21 ng/ml to 106.82+-49.93 ng/ml (P=0.142). Changes in MMP-9 concentration was the only factor associated with favorable outcomes (P=0.008, OR=5.13, 95% CI: 1.53-17.28). Conclusions: Elevated MMP-9 concentration is a potential prognosis biomarker in patients with SSNHL. These findings are in line with auto-immune diseases and indicate immune disorder is mainly pathogenesis in SSNHL. Keywords Sudden sensorineural hearing loss; Matrix metalloprotease 9; Immune disorder; prognosis; Enzyme-linked immunosorbent assay
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.